The introduction marks a significant industry advancement with the promise of a longer-lasting and highly efficient new tool — and the potential to greatly reduce the need for re-application — in the fight to protect public health.
ORLANDO, Fla. (PRWEB) February 26, 2019
MGK (http://www.mgk.com) today introduced Sumilarv® 0.5G, a mosquito larvicide that delivers a distinct mode of action and sets new standards for efficacy and duration of activity, at the annual meeting of the American Mosquito Control Association (AMCA). The introduction marks a significant industry advancement with the promise of a longer-lasting and highly efficient new tool — and the potential to greatly reduce the need for re-application — in the fight to protect public health.
“Sumilarv 0.5G brings the globally proven efficacy of pyriproxyfen to the U.S. vector control market for the first time, providing distinct class with regard to mode of action that's unlike other larvicide available in the U.S. today,” said Dr. Jennifer Williams, an MGK entomologist and recognized expert in vector control. Dr. Williams presented data showing that Sumilarv 0.5G is up to 50 times more effective than methoprene and up to 500 times more effective than spinosad, achieving mosquito toxicity at dramatically lower dose rates than comparable products. This distinct mode of action and low-dose toxicity make Sumilarv 0.5G an ideal addition to a rotational strategy for resistance mitigation.
The dense, granular sand-like formulation is easy to apply and sinks in water, where it naturally binds to organic matter and concrete — resisting flushing and dilution. Extensive field studies have demonstrated that Sumilarv 0.5G delivers reliable larval control after just a single dose. “This unmatched duration of activity enables mosquito abatement organizations to greatly reduce the frequency and costs of re-application,” said Dr. Williams.
Mosquito abatement organizations across the U.S. have tested Sumilarv 0.5G in applications like water retention ponds, livestock lagoons and other mosquito breeding sites, confirming its long-lasting efficacy. Dr. Stephen Manweiler, Executive Director of the Metropolitan Mosquito Control District of Minneapolis, Minnesota reported that “in 2017, tests of Sumilarv 0.5G provided effective season-long control (June-September) of larval mosquitoes including Culex in catch basins with just one treatment.”
Sumilarv 0.5G is currently available for use in any application that does not connect with a natural body of water. The Sumilarv 0.5G larvicide joins proven MGK botanical adulticides and barrier sprays that enabled more targeted treatments, providing a comprehensive vector control toolset. To learn more, visit http://www.mgk.com.
MGK develops and delivers a broad range of efficacious and cost-effective vector control solutions that help agencies limit vector populations, supporting these agencies in their efforts to mitigate the spread of vectored diseases and protect the health of the people they serve. In addition, MGK develops and delivers a broad portfolio of branded insect control products based primarily on natural pyrethrum and synthetic pyrethroids, as well as custom solutions for insecticide manufacturers around the world. The entire range of MGK branded products and custom solutions empower insect control professionals and organizations to achieve effective insect control with a lower environmental impact. For more information on MGK, visit http://www.mgk.com.